

CVD escalation therapy for secondary prevention (update) committee meeting 1

Date: 30/1/2023

Location: Virtual via Zoom

Minutes: Final

Committee members present:	
Beverley Bostock	
Chris Clark	
Hugh Gallagher	
Satwinder Kaur	
Paul Leeson	
Joseph Mills (Chair)	
Riyaz Patel (Topic adviser)	
David Preiss	
Ruth Price	
Chakravarthi Rajkumar (Co-opted member)	
Eduard Shantsila	
Wayne Sunman	
Colin Wilkinson	

In attendance:		
Serena Carville	Associate Director/Guideline Lead	
Catrina Charlton	Guideline Commissioning Manager	
Sharonjeet Chohan	Guideline Coordinator	
Stephen Deed	Information Specialist	
Alfredo Mariani	Technical Analyst (Economics)	
Joanna Perkin	Medical Editor	
Eleanor Samarasekera	Senior Systematic Reviewer	
Amelia Unsworth	Senior Project Manager	
Melina Vasileiou	Technical Analyst	

4.0.03 DOC Cmte minutes

David Wonderling	Head of Health Economics	
Miaoqing Yang	Technical Analyst (Economics)	

Observers:

None

Apologies:

Nigel Beckett	Committee member
Mark Glover	Committee member
Lina Gulhane	Head of Information Specialists, GDT NGC
Aroon Hingorani	Co-opted member
Kate Lovibond	Health Economics Lead

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 1st meeting on CVD escalation therapy for secondary prevention.

The Chair welcomed BB, Advance Nurse Practitioner, to replace JMa on the committee; ES, General Practitioner, to increase primary care representation on the committee for this topic; SCh, NICE guideline coordinator for this topic; SD, Information Specialist, covering for LG for this meeting; MV, NICE Technical Analyst for this topic; and MY, NICE Economic Technical Analyst for this topic.

The Chair informed the Committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included: discussion of the plans for the economic model and the clinical review protocol.

2. Confirmation of matters under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were:

- Treatment target for the escalation of therapy for secondary prevention for CVD.

The Chair asked everyone to verbally declare any interests in addition to those

4.0.03 DOC Cmte minutes

previously declared.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
None	n/a	n/a	n/a	n/a

No new declarations were received therefore no action was required.

The Chair and a senior member of the Developer's team reviewed the declarations of interest register for interests previously declared and noted that DP has a previously declared interest whereby he is an investigator and joint grant holder on the ORION-4 trial of inclisiran, funded by Novartis. The Chair and a senior member of the developer team agreed that DP is not excluded from the discussions in this piece of work, as this update will not make recommendations on sequencing of medicines or update the associated NICE technology appraisals. Therefore no further action was required.

3. Update on health economics

The Committee was given a presentation on the plans for the economic model.

4. Update on clinical review

The Committee was given a presentation on the draft clinical review protocol.

5. Any other business

None

Date of next meeting: 9/3/23

Location of next meeting: Virtual via Zoom